Affimed NV has a consensus price target of $9.6 based on the ratings of 30 analysis. The 3 most-recent analyst ratings were released by Laidlaw & Co., HC Wainwright & Co., and HC Wainwright & Co. on June 13, 2024, June 13, 2024, and June 3, 2024, respectively. With an average price target of $15 between Laidlaw & Co., HC Wainwright & Co., and HC Wainwright & Co., there's an implied 206.12% upside for Affimed NV from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
06/13/2024 | Buy Now | 410.2% | Laidlaw & Co. | Yale Jen | $15 → $25 | Maintains | Buy | Get Alert |
06/13/2024 | Buy Now | 104.08% | HC Wainwright & Co. | Swayampakula Ramakanth | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
06/03/2024 | Buy Now | 104.08% | HC Wainwright & Co. | Swayampakula Ramakanth | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
04/01/2024 | Buy Now | 410.2% | Wells Fargo | Yanan Zhu | $30 → $25 | Maintains | Overweight | Get Alert |
04/01/2024 | Buy Now | — | Cantor Fitzgerald | Li Watsek | — | Reiterates | → Overweight | Get Alert |
04/01/2024 | Buy Now | 2.04% | Stifel | Bradley Canino | $1 → $5 | Maintains | Hold | Get Alert |
04/01/2024 | Buy Now | 104.08% | HC Wainwright & Co. | Swayampakula Ramakanth | $5 → $10 | Maintains | Buy | Get Alert |
11/15/2023 | Buy Now | 2.04% | HC Wainwright & Co. | Swayampakula Ramakanth | → $50 | Reiterates | Buy → Buy | Get Alert |
09/25/2023 | Buy Now | 42.86% | Cantor Fitzgerald | Li Watsek | → $70 | Reiterates | Overweight → Overweight | Get Alert |
09/12/2023 | Buy Now | 42.86% | Cantor Fitzgerald | Li Watsek | → $70 | Reiterates | Overweight → Overweight | Get Alert |
09/07/2023 | Buy Now | 42.86% | Cantor Fitzgerald | Li Watsek | → $70 | Reiterates | Overweight → Overweight | Get Alert |
08/11/2023 | Buy Now | 22.45% | Truist Securities | Srikripa Devarakonda | $80 → $60 | Maintains | Buy | Get Alert |
08/11/2023 | Buy Now | 2.04% | HC Wainwright & Co. | Swayampakula Ramakanth | → $50 | Reiterates | Buy → Buy | Get Alert |
08/08/2023 | Buy Now | 22.45% | Berenberg | Andy Chen | → $60 | Assumes | → Buy | Get Alert |
06/05/2023 | Buy Now | 2.04% | HC Wainwright & Co. | Swayampakula Ramakanth | $60 → $50 | Maintains | Buy | Get Alert |
05/24/2023 | Buy Now | 22.45% | HC Wainwright & Co. | Swayampakula Ramakanth | → $60 | Reiterates | Buy → Buy | Get Alert |
03/27/2023 | Buy Now | 42.86% | Wells Fargo | Yanan Zhu | → $70 | Assumes | → Overweight | Get Alert |
03/24/2023 | Buy Now | -79.59% | Stifel | Bradley Canino | $20 → $10 | Maintains | Hold | Get Alert |
03/24/2023 | Buy Now | 22.45% | HC Wainwright & Co. | Swayampakula Ramakanth | → $60 | Reiterates | → Buy | Get Alert |
12/12/2022 | Buy Now | 42.86% | Wells Fargo | James Shin | $80 → $70 | Maintains | Overweight | Get Alert |
12/12/2022 | Buy Now | 22.45% | Piper Sandler | Do Kim | $70 → $60 | Maintains | Overweight | Get Alert |
12/12/2022 | Buy Now | 22.45% | SVB Leerink | Daina Graybosch | $100 → $60 | Maintains | Outperform | Get Alert |
12/12/2022 | Buy Now | 22.45% | HC Wainwright & Co. | Swayampakula Ramakanth | → $60 | Initiates | → Buy | Get Alert |
10/10/2022 | Buy Now | -59.18% | Stifel | Bradley Canino | $90 → $20 | Downgrade | Buy → Hold | Get Alert |
06/23/2022 | Buy Now | 83.67% | SVB Leerink | Daina Graybosch | $100 → $90 | Maintains | Outperform | Get Alert |
03/31/2022 | Buy Now | 42.86% | Piper Sandler | Do Kim | → $70 | Initiates | → Overweight | Get Alert |
02/23/2022 | Buy Now | 144.9% | Cantor Fitzgerald | Li Watsek | → $120 | Initiates | → Overweight | Get Alert |
10/21/2021 | Buy Now | 104.08% | Truist Securities | Srikripa Devarakonda | → $100 | Initiates | → Buy | Get Alert |
10/12/2021 | Buy Now | 144.9% | SVB Leerink | Daina Graybosch | $130 → $120 | Maintains | Outperform | Get Alert |
09/30/2021 | Buy Now | 144.9% | Stifel | Bradley Canino | → $120 | Initiates | → Buy | Get Alert |
The latest price target for Affimed (NASDAQ:AFMD) was reported by Laidlaw & Co. on June 13, 2024. The analyst firm set a price target for $25.00 expecting AFMD to rise to within 12 months (a possible 410.20% upside). 14 analyst firms have reported ratings in the last year.
The latest analyst rating for Affimed (NASDAQ:AFMD) was provided by Laidlaw & Co., and Affimed maintained their buy rating.
There is no last upgrade for Affimed
The last downgrade for Affimed NV happened on October 10, 2022 when Stifel changed their price target from $9 to $2 for Affimed NV.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Affimed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Affimed was filed on June 13, 2024 so you should expect the next rating to be made available sometime around June 13, 2025.
While ratings are subjective and will change, the latest Affimed (AFMD) rating was a maintained with a price target of $15.00 to $25.00. The current price Affimed (AFMD) is trading at is $4.90, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.